Search

Displaying results 6411 - 6420 of 10000 in total
  1. Drug

    Seliciclib

    go.drugbank.com/drugs/DB06195
    Investigational

    R-roscovitine (Seliciclib or CYC202) is a cyclin-dependent kinase (CDK) inhibitor that preferentially inhibits multiple enzyme targets including CDK2, CDK7 and CDK9, which alter the growth phase of treated … Developed by Cyclacel, seliciclib is being researched for the treatment of non-small cell lung cancer (NSCLC), leukemia, HIV infection, herpes simplex infection, and the mechanisms of chronic inflammation

  2. Drug

    Egaptivon pegol

    go.drugbank.com/drugs/DB05202
    Investigational

    Egaptivon pegol, formerly known as ARC1779, is a therapeutic aptamer antagonist of the A1 domain of von Willebrand Factor (vWF), the ligand for receptor glycoprotein 1b on platelets. … Egaptivon pegol is being investigated for the treatment of thrombotic thrombocytopenic purpura and acute coronary syndromes.

  3. Drug

    Farnesol

    go.drugbank.com/drugs/DB02509
    Investigational

    It is an intermediate step in the biological synthesis of cholesterol from mevalonic acid in vertebrates. It has a delicate odor and is used in perfumery.

  4. Drug

    Allogenic Donor CD362-enriched Human Umbilical Cord-derived Mesenchymal Stem Cells

    go.drugbank.com/drugs/DB15731
    Investigational

    Enrichment of CD362 expression in MSCs is being investigated for its role in immune modulation of injured tissue. … The isolated cells are expanded in culture and are able to be used allogenically -- meaning that one donor’s cells can be given to other unrelated patients.

  5. Drug

    Isothipendyl

    go.drugbank.com/drugs/DB08802
    Investigational

    Isothipendyl is an antihistamine and anticholinergic used as an antipruritic.

  6. Drug

    Flavin adenine dinucleotide

    go.drugbank.com/drugs/DB03147
    Approved

    (Lehninger, Principles of Biochemistry, 1982, p972) Flavin adenine dinucleotide is approved for use in Japan under the trade name Adeflavin as an ophthalmic treatment for vitamin B2 deficiency.

  7. Drug

    Bithionol

    go.drugbank.com/drugs/DB04813
    ApprovedWithdrawn

    Bithionol, formerly marketed as an active ingredient in various topical drug products, was shown to be a potent photosensitizer with the potential to cause serious skin disorders. … Approvals of the NDA's for bithionol drug products were withdrawn on October 24, 1967 (see the Federal Register of October 31, 1967 (32 FR 15046)).

  8. Drug

    Osanetant

    go.drugbank.com/drugs/DB04872
    Investigational

    In a review of its R&D portfolio, the company announced in August 2005 that it would cease any further development of osanetant. … Developed by Sanofi-Aventis (formerly Sanofi-Synthelabo), osanetant (SR-142801) is an NK3 receptor antagonist which was under development for the treatment of schizophrenia and other Central Nervous System

  9. Drug

    Xanthium strumarium pollen

    go.drugbank.com/drugs/DB10356
    Approved

    Xanthium strumarium pollen is the pollen of the Xanthium strumarium plant. Xanthium strumarium pollen is mainly used in allergenic testing.

  10. Drug

    Zea mays pollen

    go.drugbank.com/drugs/DB10357
    Approved

    Zea mays pollen is the pollen of the Zea mays plant. Zea mays pollen is mainly used in allergenic testing.